Announced
Completed
Financials
Tags
Health Care Services
Friendly
Joint Venture
United Kingdom
consumer health
Private
Cross Border
Majority
Single Bidder
Completed
Synopsis
GlaxoSmithKline, a British pharmaceutical company, and Pfizer, an American pharmaceutical corporation, formed a £9.8bn joint venture to create a premier global consumer healthcare company with robust iconic brands. The deal announced is ending to a yearlong process by Pfizer to shed its consumer business, as it and other pharmaceutical companies focus more on higher-margin prescription-drugs. Glaxo has been pursuing the same focus, though has until now stayed committed to its consumer business, which its chief executive led before her promotion to the top job. Glaxo will hold a 68% stake and Pfizer the remaining 32% of the new joint venture, which generated combined sales of $12.7bn last year.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.